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See related research by Jacob et al., http://ccforum.com/content/18/6/656In a meta-analysis of cardiac surgery trials, we showed
that hydroxyethyl starch increases postoperative blood
loss, blood product transfusion and reoperation for bleed-
ing [1]. Citing that meta-analysis, the US Food and Drug
Administration determined excess bleeding to be a class
effect of hydroxyethyl starch solutions and issued a safety
warning [2].
Jacob and colleagues report a new meta-analysis
suggesting lower perioperative blood loss with tetrastarch
than albumin across three trials [3]. However, postoperative
blood loss was in the opposite direction (Figure 1). By
imputing key unreported data instead of contacting the trial
investigators, Jacob and colleagues introduced major errors
favoring tetrastarch; for example, inflating the blood loss
difference in one trial by 2.3-fold. Furthermore, the other
two trials were confounded by exposure of one group to
both test fluids. The potential distortion is highlighted by a
randomized trial in which coadministration of low-dose
albumin with tetrastarch reduced blood loss by 21%
(P < 0.05) versus tetrastarch alone [4]. Without confounding
the blood loss differences would almost certainly have been
larger, and any meta-analysis incorporating the confounded
trials is likely to be biased in favor of tetrastarch.
Their finding of lower blood loss with tetrastarch
than pentastarch is attributable to publication bias,
since an unpublished trial with higher blood loss and
more frequent reoperation for bleeding after tetrastarch
was omitted [1,5]. The omitted trial had been submitted
to the US Food and Drug Administration in a New
Drug Application by the same tetrastarch manufacturer
who commissioned the new meta-analysis. That trial was
included in two previous meta-analyses [1,5].
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Figure 1 Partially corrected meta-analysis of postoperative blood loss in the three trials included by Jacob and colleagues comparing
tetrastarch with albumin [3]. Upon request, individual patient postoperative blood loss data were supplied by Niemi and colleagues [6] and
the means and standard deviations of cumulative 24-hour postoperative blood loss by Choi and colleagues [7]. The data provided by Niemi and
colleagues reveal that the true blood loss difference in their trial was 41 ml, not 95 ml as imputed by Jacob and colleagues. Both groups in the
trial by Hanart and colleagues received albumin postoperatively [8], while Choi and colleagues infused tetrastarch in both groups postoperatively.
Reliable correction for confounding in those two trials is not feasible, so these data are subject to bias in favor of tetrastarch. Test fluid administration
was limited to the postoperative period in the trial of Niemi and colleagues. Data combined under a fixed-effects model. Error bars indicate 95%
confidence interval (CI). Data points scaled according to meta-analytic weight. SD, standard deviation; SMD, standardized mean difference.
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